No takes yet. Share an insight, caveat, or question.
Systematic review demonstrates survival benefits of neoadjuvant therapy in borderline resectable and locally advanced pancreatic cancer, suggesting improved management strategies.
Le et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: